Newbury Pharmaceuticals (NEWBRY.ST) Stock Analysis & AI Equity Report
Newbury Pharmaceuticals (NEWBRY.ST) overview
Newbury Pharmaceuticals (NEWBRY.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Newbury Pharmaceuticals reported revenue of SEK 0m and operating profit of SEK -20.6m; the year-end share price was 2.59 SEK and market capitalisation was SEK 64.4m. Newbury Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Newbury Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-01-19. Data will be refreshed during report generation.
About Newbury Pharmaceuticals
Newbury Pharmaceuticals AB is a Swedish hybrid pharmaceutical company focused on the Nordic region and selective international sales. It develops a portfolio of in-licensed and licensed medicines and acts as an exclusive distributor and local representative for partners. Its main focus areas include specialty and branded treatments in oncology, rare diseases, and neurology.
Generate the Newbury Pharmaceuticals report
Newbury Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Newbury Pharmaceuticals and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.